Brain Tau Imaging: Food and Drug Administration Approval of ¹⁸F-Flortaucipir Injection

Abstract

Alzheimer disease (AD) is the most common of neurodegenerative dementias. Currently, there are more than 5.8 million Americans with AD. Worldwide, there are at least 50 million people with AD or other dementias, and these numbers are projected to triple by 2050 ([1][1]). Timely and accurate